Avobis Bio Reveals Expanded Data from STOMP2 Clinical Trial
Avobis Bio LLC, a pioneering clinical-stage company focused on innovative implantable cell therapies, recently announced promising expanded primary analysis results from the randomized STOMP2 trial. These findings are set to be presented at the upcoming European Crohn's and Colitis Organisation (ECCO) Congress, highlighting significant progress in addressing Crohn's perianal fistulas.
Favorable Outcomes for Crohn's Perianal Fistulas
The new cohort's outcomes show consistency with previously reported results from randomized groups, offering a glimmer of hope for those suffering from Crohn's perianal fistulas. Dr. David A Schwartz, a lead investigator and respected Professor of Medicine, will discuss these results during his presentation at the ECCO Congress.
Insights from Dr. Schwartz
In his presentation, Dr. Schwartz is expected to share important data regarding the effectiveness of AVB-114. He commented that, "The expanded sample size enhances our confidence in the safety and efficacy profile of AVB-114, which is crucial in treating this severe complication of Crohn's disease." This sentiment underscores the critical nature of the findings as they relate to patient outcomes.
Ensuring Developmental Progress
Avobis Bio is committed to advancing its therapeutic solutions, actively engaging with the U.S. Food and Drug Administration (FDA) to expedite its development plan for AVB-114. The recent meeting with the FDA emphasized the company's dedication to addressing the pressing needs of patients suffering from Crohn's disease. Dr. Tiffany Brown, CEO of Avobis Bio, expressed optimism regarding the ongoing fundraising endeavors and the preparation for phase 3 trials.
What are Crohn's Perianal Fistulas?
Perianal fistulas are debilitating conditions characterized by painful tunneling wounds connecting the rectum or anus to the skin, often leading to severe complications like uncontrolled drainage, pain, and heightened infection risk. Current standard treatments have left many patients without sustainable healing, leading to increased suffering and numerous surgical interventions.
Overview of AVB-114
AVB-114 stands apart as the only clinical-stage implantable cell therapy specifically designed to tackle the healing challenges associated with Crohn's perianal fistulas. This innovative therapy combines living cells with a biodegradable material that promotes tissue generation and healing signals, aiming to provide a groundbreaking solution for affected individuals.
FDA's Designation and Future Prospects
Encouragingly, AVB-114 has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, signaling the agency’s support for the expedited development of this potentially life-changing therapy. This designation not only offers regulatory advantages but also enhances collaboration between the company and senior FDA management.
Understanding STOMP2's Design
The STOMP2 trial is a meticulously designed phase 2 study aimed at evaluating AVB-114's potential. It employs a randomized, open-label framework, ensuring rigorous assessment of treatment efficacy. Participants include those with a single, persistent perianal fistula who have not responded to prior therapies.
The Study Process
The trial comprises two parts: the first phase details the screening, randomization, and treatment followed by a key analysis at Week 36. Participants in this group were selectively randomized to receive either standard care or AVB-114 treatment. Subsequently, those in the control arm who did not initially receive the investigational product were allowed to cross over to AVB-114 under certain conditions during the second phase of the study.
About Avobis Bio
Avobis Bio is driven by a mission to improve the lives of patients facing debilitating health conditions. The company's innovative approach leverages the power of biology to develop curative therapies aimed at healing damaged tissues. Their commitment to research and patient care highlights their role as a leader in developing novel treatment options.
Frequently Asked Questions
What is the STOMP2 trial?
STOMP2 is a phase 2 clinical trial testing the efficacy of AVB-114 for treating Crohn's perianal fistulas through a randomized, wait-list controlled method.
What are the main findings from the STOMP2 trial?
The expanded primary analysis results show that AVB-114 demonstrated similar effectiveness and favorable safety through 9 months, offering hope for better treatment options.
How does AVB-114 work?
AVB-114 combines living cells and a bioabsorbable material to stimulate tissue generation and healing signals for treating perianal fistulas.
What support has Avobis Bio received from the FDA?
AVB-114 has received the RMAT designation from the FDA, facilitating a collaborative developmental approach and expedited access to regulatory support.
Why are Crohn's perianal fistulas challenging to treat?
Many patients do not achieve lasting healing with current treatments, leading to prolonged suffering and multiple surgical interventions due to the condition's complexity.
